Sanofi walks away from MyoKardia heart drug partnership, long before key data readout

Last June, MyoKardia launched its keenly anticipated pivotal trial for its genetically targeted lead heart drug. Data are expected next year, but partner Sanofi is not waiting around. On Wednesday, the San Francisco-based biotech said its French partner had elected to cease their partnership that was forged in 2014.